These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
167 related items for PubMed ID: 7682352
1. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. Wiesner RH, Porayko MK, Wahlstrom HE, Gores GJ, Kamath PS, Hay JE, Krom RA. Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352 [No Abstract] [Full Text] [Related]
2. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. Woodle ES, Perdrizet GA, So S, Jendrisak MD, White HM, Marsh JW. Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360 [No Abstract] [Full Text] [Related]
3. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. Bismuth H. Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415 [No Abstract] [Full Text] [Related]
4. Incidence and patterns of rejection using different induction therapies in liver transplant recipients. Elkashab M, Reizig M, Greig PD, Cameron R, Phillips MJ, Chung S, Cattral M, Levy G. Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835 [No Abstract] [Full Text] [Related]
5. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. Woodle ES, So S, Jendrisak MD, Perdrizet GA, White HM, Marsh JW. Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358 [No Abstract] [Full Text] [Related]
6. [Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases]. Cherqui D, Duvoux C, Charlotte F, Humeres R, Lauzet JY, Métreau JM, Salvat A, Rotman N, Julien M, Fagniez PL. Gastroenterol Clin Biol; 1994 Apr; 18(2):115-22. PubMed ID: 8013792 [Abstract] [Full Text] [Related]
7. FK 506 rescue therapy: early conversion improves efficacy. Woodle ES, Perdrizet GA, So S, Jendrisak MD, White HM, Marsh JW. Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359 [No Abstract] [Full Text] [Related]
9. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. Lewis WD, Jenkins RL, Burke PA, Winn KM, Shaffer D, Lopez R, Monaco AP. Transplant Proc; 1991 Dec; 23(6):2989-91. PubMed ID: 1721336 [No Abstract] [Full Text] [Related]
10. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. Woodle ES, Perdrizet GA, So SK, White HM, Marsh JW. Clin Transplant; 1995 Feb; 9(1):45-52. PubMed ID: 7537988 [Abstract] [Full Text] [Related]
11. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation. Lange D, Bechstein WO, Blumhardt G, Lemmens P, Schattenfroh N, Neuhaus P. Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207 [No Abstract] [Full Text] [Related]
12. Cyclosporine A monitoring in liver transplant. Tisone G, Vennarecci G, Pisani F, Pieragostini E, Alciati E, Casciani CU. Transplant Proc; 1994 Oct; 26(5):2691-2. PubMed ID: 7940842 [No Abstract] [Full Text] [Related]
13. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. Olivari MT, Jessen ME, Baldwin BJ, Horn VP, Yancy CW, Ring WS, Rosenblatt RL. J Heart Lung Transplant; 1995 Oct; 14(1 Pt 1):127-35. PubMed ID: 7727461 [Abstract] [Full Text] [Related]
14. CsA levels in the early posttransplant period--predictive of chronic rejection in liver transplantation? Soin AS, Rasmussen A, Jamieson NV, Watson CJ, Friend PJ, Wight DG, Calne RY. Transplantation; 1995 Apr 27; 59(8):1119-23. PubMed ID: 7732557 [Abstract] [Full Text] [Related]
15. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study. Cherqui D, Duvoux C, Salvat A, Lauzet JY, Metreau JM, Julien M, Fagniez PL, Dhumeaux D. Transplant Proc; 1995 Feb 27; 27(1):1134-5. PubMed ID: 7878824 [No Abstract] [Full Text] [Related]
16. FK 506 treatment of intractable rejection after liver transplantation. Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R. Transplant Proc; 1993 Aug 27; 25(4):2686-7. PubMed ID: 7689276 [No Abstract] [Full Text] [Related]
17. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? Dé P, Bechstein WO, Blumhardt G, Lange D, Schattenfroh N, Neuhaus P. Transplant Proc; 1993 Aug 27; 25(4):2693-4. PubMed ID: 7689279 [No Abstract] [Full Text] [Related]
18. Short- and long-term cyclosporine dosage in liver transplantation. McCaughan GW, Bookallil MJ, Sheil AG. Transplant Proc; 1994 Oct 27; 26(5):2674-5. PubMed ID: 7940837 [No Abstract] [Full Text] [Related]
19. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J. Transplant Proc; 1993 Feb 27; 25(1 Pt 1):635-7. PubMed ID: 7679826 [No Abstract] [Full Text] [Related]
20. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmüller T, Christe W, Hopf U, Lobeck H, Neuhaus P. Transplant Proc; 1995 Feb 27; 27(1):1117-20. PubMed ID: 7533359 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]